
Cantargia Q2 2024 - CAN10 Proof-of-Mechanism

Redeye comments on Cantargia's Q2 report. CAN10 is progressing according to plan with proof-of-mechanism established in the single-dose cohorts. The study of nadunolimab in triple-negative breast cancer has been delayed by up to six months with readout now expected by H1 2025.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

[Cantargia Q2 2024 - CAN10 Proof-of-Mechanism](#)